78 related articles for article (PubMed ID: 15068897)
21. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
[TBL] [Abstract][Full Text] [Related]
22. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
Suárez L; Vidriales MB; Moreno MJ; López A; García-Laraña J; Pérez-López C; Tormo M; Lavilla E; López-Berges MC; de Santiago M; San Miguel JF; Orfao A;
Haematologica; 2005 Jan; 90(1):54-9. PubMed ID: 15642669
[TBL] [Abstract][Full Text] [Related]
23. Expression of multidrug resistance-related markers in primary neuroblastoma.
Lu QJ; Dong F; Zhang JH; Li XH; Ma Y; Jiang WG
Chin Med J (Engl); 2004 Sep; 117(9):1358-63. PubMed ID: 15377429
[TBL] [Abstract][Full Text] [Related]
24. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
[TBL] [Abstract][Full Text] [Related]
25. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
Tourneur L; Delluc S; Lévy V; Valensi F; Radford-Weiss I; Legrand O; Vargaftig J; Boix C; Macintyre EA; Varet B; Chiocchia G; Buzyn A
Cancer Res; 2004 Nov; 64(21):8101-8. PubMed ID: 15520222
[TBL] [Abstract][Full Text] [Related]
26. A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis.
Schaich M; Koch R; Soucek S; Repp R; Ehninger G; Illmer T
Br J Haematol; 2004 May; 125(4):477-9. PubMed ID: 15142118
[TBL] [Abstract][Full Text] [Related]
27. [Multidrug resistance markers monitoring in acute myeloid leukemia cells].
Jankovicová K; Krejsek J; Kopecký O; Voglová J; Novosad J
Cas Lek Cesk; 2004; 143(7):471-5. PubMed ID: 15373290
[TBL] [Abstract][Full Text] [Related]
28. [The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
Machaczka M; Rucińska M; Jabłoński M; Skotnicki AB
Przegl Lek; 1998; 55(7-8):407-13. PubMed ID: 10021886
[TBL] [Abstract][Full Text] [Related]
29. Effects of multidrug resistance gene expression in acute erythroleukemia.
Mazzella FM; Kowal-Vern A; Shrit MA; Rector JT; Cotelingam JD; Schumacher HR
Mod Pathol; 2000 Apr; 13(4):407-13. PubMed ID: 10786807
[TBL] [Abstract][Full Text] [Related]
30. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
[TBL] [Abstract][Full Text] [Related]
31. TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression.
Asakura K; Uchida H; Miyachi H; Kobayashi H; Miyakawa Y; Nimer SD; Takahashi H; Ikeda Y; Kizaki M
Mol Cancer Res; 2004 Jun; 2(6):339-47. PubMed ID: 15235109
[TBL] [Abstract][Full Text] [Related]
32. Aberrant co-expression of CD19 and CD56 as surrogate markers of acute myeloid leukemias with t(8;21) in Taiwan.
Chen SW; Li CF; Chuang SS; Tzeng CC; Hsieh YC; Lee PS; Chen CH; Huang WT; Hwang WS; Tsao CJ
Int J Lab Hematol; 2008 Apr; 30(2):133-8. PubMed ID: 18333845
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
[TBL] [Abstract][Full Text] [Related]
34. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
35. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Dombret H; Preudhomme C; Boissel N
Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
[TBL] [Abstract][Full Text] [Related]
36. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
Shen X; Chen G; Zhu G; Fong WF
Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.
Kim JS; Eom JI; Cheong JW; Choi AJ; Lee JK; Yang WI; Min YH
Clin Cancer Res; 2007 Feb; 13(3):1019-28. PubMed ID: 17289898
[TBL] [Abstract][Full Text] [Related]
38. [Multidrug resistance mediated by membrane P-glycoprotein in acute myeloid leukemia].
Su LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):544-8. PubMed ID: 14575557
[TBL] [Abstract][Full Text] [Related]
39. CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential.
Zaidi SZ; Motabi IH; Al-Shanqeeti A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):129-30. PubMed ID: 26706848
[TBL] [Abstract][Full Text] [Related]
40. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.
Witherspoon SM; Emerson DL; Kerr BM; Lloyd TL; Dalton WS; Wissel PS
Clin Cancer Res; 1996 Jan; 2(1):7-12. PubMed ID: 9816083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
